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Background
The V3 loop is one of the few epitopes to which broadly
neutralizing antibody response can be directed. The most
potent and most broadly neutralizing anti-V3 antibody to
date is the human monoclonal antibody 447-52D. Using
NMR spectroscopy, we studied the conformation of sev-
eral V3 peptides in complex with 447-52D. The flexible V3
peptides were found to adopt a β-hairpin conformation
when bound to this antibody. Using disulfide bonds we
constrained V3 peptides to adopt a conformation similar
to those of V3 peptides bound to 447-52D.
Methods
Two cyclic peptides, P2 and P3, based on the consensus
sequence of clade-B R5 viruses were synthesized in the
form of a C4-V3 construct and compared with the linear
peptide (P1). The peptide P2 was constrained by a
disulfide bond at positions T303C/I323C and included
the entire 447-52D epitope (R304-E322); the peptide P3
was constrained closer to the GPGR turn at positions
K305C/T320C. Sera of rabbits immunized with these
three peptides were tested for the ability to neutralize a
panel of HIV-1 isolates.
Results
The peptide constrained at position T303C/I323C (P2)
elicited a more potent HIV-1 neutralizing response in
comparison with the linear P1 or the constrained peptide
P3. All 4 sera of rabbits immunized with P2 neutralized 5
out of the 7 strains tested. For the SF162 strain, which dif-
fered by three mutations from the immunizing V3-pep-
tide, 50% neutralization was achieved with average titers
greater than 1,580, at least 20-fold and 40-fold better than
the linear peptide (P1) and the other constrained peptide
(P3) immune-sera, respectively.
Conclusion
We have demonstrated that constrained V3 peptides can
elicit strong HIV-1 neutralizing response that is consider-
ably more potent in comparison with linear peptide
immune-sera given that the constraint is optimally
located within the V3 epitope to include the entire V3
epitope recognized by the 447-52D antibody.
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